Uno studio su Guselkumab nei partecipanti pediatrici con malattia di Crohn da moderatamente a gravemente attiva (MACARONI-23)
Uno studio di piattaforma di fase 3, multicentrico, randomizzato, sull'inibizione di p19 del percorso IL-23 per stabilire l'efficacia nella malattia di Crohn pediatrica
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Study Contact
- Numero di telefono: 844-434-4210
- Email: Participate-In-This-Study1@its.jnj.com
Luoghi di studio
-
-
-
Nedlands, Australia, 6009
- Reclutamento
- Perth Children's Hospital
-
South Brisbane, Australia, 4101
- Reclutamento
- Mater Hospital Brisbane
-
Westmead, Australia, 2145
- Reclutamento
- The Children's Hospital at Westmead
-
-
-
-
-
Vienna, Austria, 1090
- Reclutamento
- AKH - Medizinische Universitat Wien
-
-
-
-
-
Brussels, Belgio, 1090
- Reclutamento
- Universitair Ziekenhuis Brussel
-
Brussels, Belgio, 1200
- Reclutamento
- Cliniques Universitaires Saint Luc
-
Ghent, Belgio, 9000
- Reclutamento
- Universitair Ziekenhuis Gent
-
Leuven, Belgio, 3000
- Reclutamento
- UZ Leuven
-
-
-
-
-
Campinas, Brasile, 13060-904
- Reclutamento
- Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro
-
Curitiba, Brasile, 80250-060
- Reclutamento
- Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro
-
Goiânia, Brasile, 74605-020
- Reclutamento
- Universidade Federal de Goias - Hospital das Clinicas da UFG
-
Porto Alegre, Brasile, 90035-074
- Reclutamento
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Porto Alegre, Brasile, 90035-007
- Reclutamento
- Hospital De Clinicas De Porto Alegre
-
Vitória, Brasile, 29040-091
- Reclutamento
- Centro de Ciencias e Saude da Universidade Federal do Espirito Santo-Nucleo de Doencas Infecciosas
-
Votuporanga, Brasile, 100000
- Reclutamento
- INTEGRAL Pesquisa e Ensino
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- Reclutamento
- Iwk Health Centre
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Reclutamento
- London Health Sciences Centre Victoria Hospital
-
Toronto, Ontario, Canada, M5G 1X8
- Reclutamento
- Hospital For Sick Children
-
-
-
-
-
Busan, Corea del Sud, 48108
- Reclutamento
- Inje University Haeundae Paik Hospital
-
Daegu, Corea del Sud, 41404
- Reclutamento
- Kyungpook National University Chilgok Hospital
-
Seoul, Corea del Sud, 03080
- Reclutamento
- Seoul National University Hospital
-
Seoul, Corea del Sud, 06351
- Reclutamento
- Samsung Medical Center
-
Seoul, Corea del Sud, 120-752
- Reclutamento
- Severance Hospital Yonsei University Health System
-
-
-
-
-
Amiens, Francia, 80054
- Reclutamento
- CHU Amiens-Hopital Nord
-
Lille, Francia, 59037
- Reclutamento
- Hôpital Jeanne de FLANDRE, CHRU LILLE
-
Paris, Francia, 75019
- Reclutamento
- Hôpital Robert Debré
-
Paris, Francia, 75015
- Reclutamento
- Hôpital Necker - Enfants Malades
-
-
-
-
-
Hirosaki, Giappone, 036-8563
- Reclutamento
- Hirosaki University Hospital
-
Kagoshima, Giappone, 890-8544
- Reclutamento
- Kagoshima University Hospital
-
Kashiwa-shi, Giappone, 277-0871
- Reclutamento
- Tsujinaka Hospital Kashiwanoha
-
Kobe, Giappone, 650 0017
- Reclutamento
- Kobe University Hospital
-
Saga, Giappone, 849-8501
- Reclutamento
- Saga University Hospital
-
Sendai, Giappone, 989-3126
- Reclutamento
- Miyagi Childrens Hospital
-
Setagaya Ku, Giappone, 157 8535
- Reclutamento
- National Center for Child Health and Development
-
Tokyo, Giappone, 113-8431
- Reclutamento
- Juntendo University Hospital
-
Tsu, Giappone, 514 8507
- Reclutamento
- Mie University Hospital
-
Ube, Giappone, 755-8505
- Reclutamento
- Yamaguchi University Hospital
-
Yokohama, Giappone, 232-0024
- Reclutamento
- Yokohama City University Medical Center
-
Yokohama, Giappone, 230-8765
- Reclutamento
- Saiseikai Yokohamashi Tobu Hospital
-
-
-
-
-
Beersheba, Israele, 84101
- Reclutamento
- Soroka University Medical Center
-
Be’er Ya‘aqov, Israele, 70300
- Reclutamento
- Shamir Medical Center Assaf Harofeh
-
Jerusalem, Israele, 9103102
- Reclutamento
- Shaare Zedek Medical Center
-
Jerusalem, Israele, 9124001
- Reclutamento
- Hadassah Medical Center
-
Petah Tikva, Israele, 4920235
- Reclutamento
- Schneider Children's Medical Center
-
Rehovot, Israele, 761001
- Reclutamento
- Kaplan Medical Center
-
-
-
-
-
Alessandria, Italia, 15121
- Reclutamento
- A.O. Santi Antonio e Biagio e Cesare Arrigo
-
Bergamo, Italia, 24127
- Reclutamento
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
-
Bologna, Italia, 40124
- Reclutamento
- Ospedale Bellaria, U.O.Cardiologia Az. USL di Bologna
-
Florence, Italia, 50139
- Reclutamento
- Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
-
Milan, Italia, 20154
- Reclutamento
- Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale dei Bambini Vittore Buzzi
-
Roma, Italia, 161
- Reclutamento
- AOU Policlinico Umberto I
-
-
-
-
-
Nordbyhagen, Norvegia, 1474
- Reclutamento
- Akershus Universitetssykehus HF
-
Oslo, Norvegia, 424
- Reclutamento
- Oslo University Hospital
-
Tromsø, Norvegia, 9038
- Reclutamento
- Universitetssykehuset Nord-Norge HF
-
Trondheim, Norvegia, 7030
- Reclutamento
- St. Olavs Hospital
-
-
-
-
-
Rotterdam, Olanda, 3015 GD
- Reclutamento
- Erasmus Medisch Centrum
-
-
-
-
-
Rzeszów, Polonia, 35-302
- Reclutamento
- Korczowski Bartosz Gabinet Lekarski
-
Warsaw, Polonia, 04 501
- Reclutamento
- WIP Warsaw IBD Point Profesor Kierkus
-
Warsaw, Polonia, 04 730
- Reclutamento
- Instytut Pomnik Centrum Zdrowia
-
-
-
-
-
Braga, Portogallo, 4710-243
- Reclutamento
- Hospital de Braga
-
Lisbon, Portogallo, 1649-035
- Reclutamento
- Centro Hospitalar de Lisboa Norte Hospital Santa Maria
-
Porto, Portogallo, 4200-319
- Reclutamento
- Centro Hospitalar de Sao Joao E.P.E.
-
-
-
-
-
Glasgow, Regno Unito, G51 4TF
- Reclutamento
- Royal Hospital for Sick Children
-
London, Regno Unito, WC1N 3JH
- Reclutamento
- Great Ormond Street Hospital
-
Manchester, Regno Unito, M13 9WL
- Reclutamento
- Royal Manchester Children's Hospital
-
Manchester, Regno Unito, M13 9WL
- Reclutamento
- Nowgen Centre, Research and Innovation
-
Oxford, Regno Unito, OX3 9DU
- Reclutamento
- John Radcliffe Hospital
-
Sheffield, Regno Unito, S10 2TH
- Reclutamento
- Sheffield Children's Hospital
-
-
-
-
-
Córdoba, Spagna, 14004
- Reclutamento
- Hosp Reina Sofia
-
Sabadell, Spagna, 8208
- Reclutamento
- Corporacio Sanitari Parc Tauli
-
Valencia, Spagna, 46026
- Reclutamento
- Hosp. Univ. I Politecni La Fe
-
-
-
-
California
-
Los Angeles, California, Stati Uniti, 90048
- Reclutamento
- Cedars Sinai Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Stati Uniti, 06106
- Reclutamento
- Connecticut Children's Medical Center
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Reclutamento
- Emory University
-
Atlanta, Georgia, Stati Uniti, 30342
- Reclutamento
- Children's Center for Digestive Health Care
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202-5225
- Reclutamento
- Riley Hospital for Children
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02115
- Reclutamento
- Boston Childrens Hospital
-
-
New Jersey
-
Morristown, New Jersey, Stati Uniti, 07960
- Reclutamento
- Goryeb Children's Hospital
-
-
New York
-
New York, New York, Stati Uniti, 10029
- Reclutamento
- Icahn School of Medicine at Mount Sinai
-
New York, New York, Stati Uniti, 10032
- Reclutamento
- Columbia University Medical Center
-
New York, New York, Stati Uniti, 10021-5663
- Reclutamento
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center
-
-
Ohio
-
Dayton, Ohio, Stati Uniti, 45404
- Reclutamento
- The Children's Medical Center of Dayton
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- Children's Hospital of Philadelphia
-
-
Texas
-
Fort Worth, Texas, Stati Uniti, 76104
- Reclutamento
- Cook Childrens Medical Center
-
-
Vermont
-
Colchester, Vermont, Stati Uniti, 05446
- Reclutamento
- University of Vermont Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
- Participants must have moderately to severely active CD (as defined by a baseline Pediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=] 30)
- Participants must have endoscopy with evidence of active CD defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0
- Participants must have a history of inadequate response, loss of response, or intolerance to immunomodulators (6-MP, AZA, or MTX), oral or IV corticosteroids, or biologic therapy/JAK inhibitor therapy; OR have a history of corticosteroid dependence; OR have a history of inadequate response to exclusive enteral nutrition (EEN)
Exclusion Criteria:
- Participants has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be anticipated to require surgery.
- Participants must not have an abscess
- Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Open-label induction phase: Guselkumab Intravenously (IV)
Participants will receive guselkumab dose IV based on their body weight during the 12-week open-label induction phase. |
Guselkumab will be administered subcutaneously.
Altri nomi:
Guselkumab will be administered intravenously.
Altri nomi:
|
|
Sperimentale: Open-label induction phase: Guselkumab Subcutaneously (SC)
Participants will receive guselkumab dose SC based on their body weight during the 12-week open-label induction phase. |
Guselkumab will be administered subcutaneously.
Altri nomi:
Guselkumab will be administered intravenously.
Altri nomi:
|
|
Sperimentale: Double-blind maintenance phase: Guselkumab SC Dose Regimen 1
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
Altri nomi:
Guselkumab will be administered intravenously.
Altri nomi:
|
|
Sperimentale: Double-blind Maintenance Phase: Guselkumab SC Dose Regimen 2
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
Altri nomi:
Guselkumab will be administered intravenously.
Altri nomi:
|
|
Sperimentale: Open-label maintenance phase: Guselkumab SC
Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
Altri nomi:
Guselkumab will be administered intravenously.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Participants with Clinical Remission at Week 52
Lasso di tempo: Week 52
|
Percentage of participants with clinical remission at Week 52 will be assessed. Clinical remission is defined as pediatric Crohn's Disease activity index (PCDAI) less than or equal to (<=) 10. |
Week 52
|
|
Percentage of Participants Who Achieve Endoscopic Response at Week 52
Lasso di tempo: Week 52
|
Percentage of participants who achieve endoscopic response at Week 52 will be assessed. Endoscopic response is defined as greater than or equal to (>=) 50 percent (%) reduction (global) and greater than (>) 50% reduction (U.S specific) from simplified endoscopic score-Crohn's Disease (SES-CD) score at baseline. |
Week 52
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Participants with Clinical Response at Week 12
Lasso di tempo: Week 12
|
Percentage of participants with clinical response at Week 12 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30. |
Week 12
|
|
Percentage of Participants with Clinical Response at Week 52
Lasso di tempo: Week 52
|
Percentage of participants with clinical response at Week 52 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30. |
Week 52
|
|
Percentage of Participants with Clinical Remission at Week 12
Lasso di tempo: Week 12
|
Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is defined as PCDAI score <=10. |
Week 12
|
|
Percentage of Participants with Endoscopic Remission at Week 52
Lasso di tempo: Week 52
|
Percentage of participants with endoscopic remission at Week 52 will be assessed. Endoscopic remission is defined as SES-CD total score <=4 and at least a 2-point reduction from baseline and no subscore >1. |
Week 52
|
|
Percentage of Participants with Corticosteroid-free Remission at Week 52
Lasso di tempo: Week 52
|
Percentage of participants with corticosteroid-free remission at Week 52 will be assessed. Corticosteroid-free remission is defined as PCDAI score <=10 at Week 52 and not receiving corticosteroids for at least 90 days before Week 52. |
Week 52
|
|
Percentage of Participants with Sustained Clinical Remission at Weeks 12, 24, and 52
Lasso di tempo: Weeks 12, 24, and 52
|
Percentage of participants with sustained clinical remission at Weeks 12, 24, and 52 will be assessed. Sustained clinical remission is defined as PCDAI <=10 at Weeks 12, 24, and 52. |
Weeks 12, 24, and 52
|
|
Percentage of Participants with Clinical remission by Patient-Reported Outcome (PRO-2)
Lasso di tempo: Week 12 and/or Week 52
|
Percentage of participants with clinical remission by PRO-2 will be assessed. Clinical remission by PRO-2 is defined as stool frequency (SF) <=3 and abdominal pain (AP) <=1 and no worsening of SF and AP from baseline. |
Week 12 and/or Week 52
|
|
Serum Concentration of Guselkumab During Induction Phase
Lasso di tempo: From Week 0 to Week 12
|
Serum concentrations of guselkumab will be assessed. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive immunoassay method. |
From Week 0 to Week 12
|
|
Trough Plasma Concentration (Ctrough) of Guselkumab During Maintenance Phase
Lasso di tempo: At Weeks 16, 24, 36, 48 and 52
|
Ctrough is defined as the serum concentration of guselkumab immediately prior (pre-dose) to the next drug administration. |
At Weeks 16, 24, 36, 48 and 52
|
|
Change from Baseline in Body Weight at Weeks 12, 24, and 52
Lasso di tempo: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Body Weight Percentiles at Weeks 12, 24, and 52
Lasso di tempo: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight percentiles at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Body Weight z-scores at Weeks 12, 24, and 52
Lasso di tempo: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight z-scores at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height at Weeks 12, 24, and 52
Lasso di tempo: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height Percentiles at Weeks 12, 24, and 52
Lasso di tempo: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height percentiles at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height z-scores at Weeks 12, 24, and 52
Lasso di tempo: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height z-scores at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height Velocity at Weeks 12, 24, and 52
Lasso di tempo: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height velocity at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Percentage of Participants with Clinical Remission
Lasso di tempo: Week 52
|
Percentage of participants with clinical remission who were assigned to guselkumab dose regimen 1 and did not receive rescue therapy at Week 52 will be assessed. Clinical remission is defined as PCDAI score <=10. |
Week 52
|
|
Percentage of Participants Who Achieve Endoscopic Response
Lasso di tempo: Week 52
|
Percentage of participants who achieve endoscopic response who were assigned to q4w maintenance therapy and did not receive rescue therapy at Week 52 will be assessed. Endoscopic response is defined as >=50% reduction (global) and >50% reduction (U.S specific) from SES-CD score at baseline. |
Week 52
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Lasso di tempo: Up to Week 64
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important. |
Up to Week 64
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Clinical Trial, Janssen Research & Development, LLC
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CR109212
- 2021-006282-37 (Numero EudraCT)
- CNTO1959PBCRD3007 (Altro identificatore: Janssen Research & Development, LLC)
- 2023-504735-41-00 (Identificatore di registro: EUCT number)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .